Logo
Logo


ISSN: 0300-9041
ISSNe: 2594-2034


Indizada en: SciELO, Índice Médico Latinoamericano, LILACS, Medline
Editada por la Federación Mexicana de Colegios de Obstetricia, y Ginecologia AC
Fundada por la Asociación Mexicana de Ginecología y Obstetricia en 1945
 

INFORMACIÓN EXCLUSIVA PARA LOS PROFESIONALES DE LA SALUD


Periodicidad: continua
Abreviatura: Ginecol Obstet Mex
ISSN: 0300-9041
ISSNe: 2594-2034
Indizada en: Scimago, Índice Médico Latinoamericano, Lilacs, Medline, Science Citation Index, Ulrich, Ebsco.

Linfoma de Burkitt en la mama durante el embarazo: reporte de un caso

Linfoma de Burkitt en la mama durante el embarazo: reporte de un caso.

Ginecol Obstet Mex. 2021; 89 (8): 647-654.

https://doi.org/10.24245/gom.v89i8.4999

Cesar Ramón Aguilar-Torres,1 Yadira Aideé Márquez-Ramírez,2 Edgar Omar Mariñelarena-Carrillo,2 Sheila Guadalupe Oropeza-Rodríguez,2 Carlos Chávez-Trillo,3 Kachira Eldadi Portillo-Chiu1

1 Servicio de Ginecología y Obstetricia.
2 Residente de Ginecología y Obstetricia.
3 Hematólogo.
Hospital Central del Estado de Chihuahua, Facultad de Medicina y Ciencias Biomédicas, Universidad Autónoma de Chihuahua, Chihuahua, México.


Corrrespondencia:

Yadira Aideé Márquez Ramírez
yadiramarquez04@gmail.com

Debe citarse como:

Aguilar-Torres CR, Márquez-Ramírez YA, Mariñelarena-Carrillo, EO, Oropeza-Rodríguez SG, Chávez-Trillo C, Portillo-Chiu KE. Linfoma de Burkitt en la mama durante el embarazo: reporte de un caso. Ginecol Obstet Mex 2021; 89 (8): 647-654. https://doi.org/10.24245/gom.v89i8.4999

Resumen

ANTECEDENTES: El linfoma de Burkitt se deriva de las células B germinales; es muy agresivo y puede tener una incidencia extraganglionar elevada, se localiza, incluso, en sitios tan infrecuentes como la mama, se relaciona con el embarazo y el puerperio.

CASO CLÍNICO: Paciente de 19 años, en curso del segundo embarazo, con parto dos años previos a su padecimiento actual, ciclos menstruales irregulares, sin método anticonceptivo. Acudió a recibir atención a un centro de primer nivel a las 22 semanas de embarazo debido al aumento de tamaño de la mama derecha, iniciado 20 días antes. En la exploración física se advirtieron: aumento de volumen, eritema e hipertermia en la mama derecha. La sonografía reportó: mama derecha con engrosamiento de piel, aumento de volumen, ecogenicidad heterogénea, vascularidad aumentada y conservada, sin adenopatías. Ante la insuficiencia se le indicó hemodiálisis, con respuesta satisfactoria. Con el reporte de la biopsia e inmunohistoquímica se estableció el diagnóstico de linfoma de Burkitt. Se le indicó quimioterapia con rituximab, etopósido, vincristina, doxorrubicina y  ciclofosfamida. El embarazo se interrumpió a las 34.4 semanas debido al estado fetal no tranquilizador, a expensas del registro cardiotocográfico no reactivo (categoría 2) y la restricción del crecimiento intrauterino tipo 1.

CONCLUSIÓN: Las masas mamarias producidas por neoplasias malignas durante el embarazo o puerperio representan un desafío diagnóstico para el clínico. El procedimiento diagnóstico y el tratamiento deben estar a cargo de un equipo multidisciplinario.

PALABRAS CLAVE: Linfoma de Burkitt; células B; mamas; embarazo; examen físico; hipertermia; sonografía; quimioterapia.

Abstract

BACKGROUND: Burkitt's lymphoma is derived from germ B cells; it is very aggressive and can have a high extranodal incidence, it is located even in sites as rare as the breast, it is associated with pregnancy and puerperium.

CLINICAL CASE: 19-year-old female patient, in the course of her second pregnancy, with childbirth two years prior to her current condition, irregular menstrual cycles, without contraceptive method. She sought care at a primary care center at 22 weeks of pregnancy due to enlargement of the right breast, which had begun 20 days earlier. Physical examination revealed: enlargement, erythema and hyperthermia in the right breast. Sonography reported: right breast with skin thickening, increased volume, heterogeneous echogenicity, increased and preserved vascularity, without adenopathies. In view of the insufficiency, hemodialysis was indicated, with satisfactory response. With the report of the biopsy and immunohistochemistry the diagnosis of Burkitt's lymphoma was established. Chemotherapy with rituximab, etoposide, vincristine, doxorubicin and cyclophosphamide was indicated. Pregnancy was terminated at 34.4 weeks due to nonreassuring fetal status at the expense of nonreactive cardiotocographic recording (category 2) and type 1 intrauterine growth restriction.

CONCLUSION: Breast masses produced by malignant neoplasms during pregnancy or puerperium represent a diagnostic challenge for the clinician. The diagnostic procedure and treatment should be performed by a multidisciplinary team.

KEYWORDS: Burkitt's lymphoma; B cells; Breast; Pregnancy; Physical examination; Hyperthermia; Sonography; Chemotherapy.

    1. Sajdak S, Englert-Golon M. Cancer in pregnancy. Ginekol Prakt 2009; 17 (3): 17-20. http://dx.doi.org/10.1007/s12262-009-0097-1
    2. Inácio Júnior ALA, Rocha BF, Botelho LFB. Burkitt’s lymphoma successfully treated in pregnancy. Rev Bras Hematol Hemoter 2015; 37 (2): 127-29. doi:10.1016/j.bjhh.2014.11.002
    3. Eastwood-Wilshere N, Turner J, Oliveira N, Morton A. Cancer in Pregnancy. Asia-Pac J Clin Oncol 2019; 15 (6): 296-308. https://doi.org/10.1111/ajco.13235
    4. Hurley TJ, McKinnell J V, Irani MS. Hematologic malignancies in pregnancy. Obstet Gynecol Clin North Am 2005; 32 (4): 595-614. doi:10.1016/j.ogc.2005.08.008
    5. Molyneux EM, Rochford R, Griffin B, Newton R, Jackson G, Menon G, Harrison CJ, Israels T, Bailey S. Burkitt's lymphoma. Lancet 2012; 379 (9822): 1234-44. doi: 10.1016/S0140-6736(11)61177-X.
    6. Jeanneret-Sozzi W, Taghian A, Epelbaum R, et al. Primary breast lymphoma: Patient profile, outcome and prognostic factors. A multicentre Rare Cancer Network study. BMC Cancer 2008; 8: 1-7. doi:10.1186/1471-2407-8-86
    7. Kassab C, Perini GF, Bollmann PW, Kerbauy FR, Hamerschlak N. Hodgkin's disease and pregnancy: case series and proposal for treatment protocol. Einstein (Sao Paulo, Brazil). 2011; 9 (2): 216-19. doi: 10.1590/s1679-45082011rc1992
    8. Surov A, Holzhausen HJ, Wienke A, Schmidt J, Thomssen C, Arnold D, Ruschke K, Spielmann RP. Primary and secondary breast lymphoma: prevalence, clinical signs and radiological features. Br J Radiol 2012; 85 (1014): e195-205. doi: 10.1259/bjr/78413721
    9. Roldán-Valadez E, García-Blanco MC, Rojas-Marín C, Sánchez-Ávila F, León-Rodríguez E, Hernández-Ortiz J. Linfoma no Hodgkin de células B con extensión secundaria a glándula mamaria: Evaluación por imagen. Gac Méd Méx 2005; 141 (1): 63-67. http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0016-38132005000100011&lng=es&nrm=iso>
    10. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006; 107 (1): 265-76. doi:10.1182/blood-2005-06-2508
    11. Bano R, Khan AI, Shahraf A, Abid M. Primary bilateral breast lymphoma: a review of literature and report of four cases from a single centre. JCAS 2016; 2 (2). https://doi.org/10.37029/jcas.v2i2.70
    12. Sabate JM, Clotet M, Torrubia S, et al. Radiologic evaluation of breast disorders related to pregnancy and lactation. Radiographics 2007; 27: 101-25. doi:10.1148/rg.27si075505
    13. Cortés X, Moncaleano JM. Asociacion de carcinoma ductal infiltrante de mama y linfoma no Hodgkin anaplásico de células B grandes. Presentacion de un caso clinico. The Free Library 01 July 2005. https://www.thefreelibrary.com/Asociacion de carcinoma ductal infiltrante de mama y linfoma no...-a0174102021>
    14. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines® ) B-Cell Lymphomas Version 4.2020 -August 13, 2020. https://www.nccn.org/professionals/physician_gls/default.aspx#b-cell>
    15. Hodby K, Fields PA. Management of lymphoma in pregnancy. Obstet Med 2009; 2 (2): 46-51. https://doi.org/10.1258/om.2009.090007
    16. Magrath I. Epidemiology: Clues to the pathogenesis of Burkitt lymphoma. Br J Haematol. 2012; 156 (6): 744-56. https://doi.org/10.1111/j.1365-2141.2011.09013.x
    17. Chedraui AP, Proano LC, Saltos FG. Linfoma no Hodgkin y embarazo: revisión. Medicina (Guayaquil) 2002; 8 (2): 150-56.
    18. Miles EF, Jacimore LL. Synchronous bilateral breast carcinoma and axillary non-Hodgkin lymphoma: A case report and review of the literature. Case Rep Oncol Med 2012; 2012: 685919. https://doi.org/10.1155/2012/685919
    19. Yang H, Lang R, Fu L. Primary breast lymphoma (PBL): A literature review. Clin Oncol Cancer Res. 2011; 8 (3): 128-132. https://doi.org/10.1007/s11805-011-0570-z
    20. Joks M, Myśliwiec K, Lewandowski K. Primary breast lymphoma. A review of the literature and report of three cases. Arch Med Sci 2011; 7 (1): 27-33. doi:10.5114/aoms.2011.20600
    21. Schillaci O, Travascio L, Lacanfora A, Ceccarelli S, Simonetti G. Rare lymphoid malignancies of the breast: Report of two cases illustrating potential diagnostic techniques. J Radiol Case Rep 2012; 6 (12): 43-50. doi:10.3941/jrcr.v6i12.11941
    22. Brandt JS, Fishman S, Magro CM. Cutaneous melanoma arising from a cesarean delivery skin scar. J Perinatol 2012; 32 (10): 807-9. https://doi.org/10.1038/jp.2011.172
    23. Cohen-Kerem R, Railton C, Oren D, Lishner M, Koren G. Pregnancy outcome following non-obstetric surgical intervention. Am J Surg 2005; 190 (3): 467-73. https://doi.org/10.1016/j.amjsurg.2005.03.033
    24. Abbassi-Ghanavati M, Greer LG, Cunningham FG. Pregnancy and laboratory studies: a reference table for clinicians. Obstet Gynecol 2009; 114 (6): 1326-31. doi: 10.1097/AOG.0b013e3181c2bde8.
    25. Elena G, Cedola A, Ramos A, et al. Guía para el manejo clínico del síndrome de lisis tumoral agudo. Arch Argent Pediatr. 2011;109(1):77-82.
    26. Brenner B, Avivi I, Lishner M. Haematological cancers in pregnancy. Lancet. 2012;379(9815):580-587. doi:10.1016/S0140-6736(11)61348-2
    27. Lishner M, Avivi I, Apperley JF, Dierickx D, Evens AM, Fumagalli M, Nulman I, Oduncu FS, Peccatori FA, Robinson S, Van Calsteren K, Vandenbroucke T, Van den Heuvel F, Amant F. Hematologic Malignancies in Pregnancy: Management Guidelines From an International Consensus Meeting. J Clin Oncol. 2016 Feb 10;34(5):501-8. doi: 10.1200/JCO.2015.62.4445.
    28. Lloyd M, McElhatton P, Carr M, Hall G, Hughes R. Methotrexate in pregnancy. Rheumatology (Oxford). 2005 May;44(5):697; author reply 698. doi: 10.1093/rheumatology/keh612.
    29. Cohen JB, Blum KA. Evaluation and management of lymphoma and leukemia in pregnancy. Clin Obstet Gynecol. 2011 Dec;54(4):556-66. doi: 10.1097/GRF.0b013e318236e68a. PMID: 22031246.
    30. Amit, O., Barzilai, M. & Avivi, I. Management of Hematologic Malignancies: Special Considerations in Pregnant Women. Drugs 75, 1725–1738 (2015). https://doi.org/10.1007/s40265-015-0464-0
    31. Hoelzer D, Walewski J, Döhner H, et al. Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: Report of a large prospective multicenter trial. Blood 2014; 124 (26): 3870-79. https://doi.org/10.1182/blood-2014-03-563627
    32. Leslie KK. Chemotherapy and pregnancy. Clin Obstet Gynecol 2002; 45: 153-164. doi: 10.1097/00003081-200203000-00015
    33. Chakravarty EF, Murray ER, Kelman A, Farmer P. Pregnancy outcomes after maternal exposure to rituximab. Blood 2011; 117 (5): 1499-1506. https://doi.org/10.1182/blood-2010-07-295444
    34. Maggen C, Dierickx D, Lugtenburg P, Laenen A, Cardonick E, et al. Obstetric and maternal outcomes in patients diagnosed with Hodgkin lymphoma during pregnancy: a multicentre, retrospective, cohort study. Lancet Haematol 2019; 6 (11): e551-e561. https://doi.org/10.1016/S2352-3026(19)30195-4

Comentarios